Sanofi and Regeneron hosted a conference call for the financial community on the results of the ODYSSEY OUTCOMES study.
- Recorded audio webcast
- Press release – March 10, 2018: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
- Press release – March 10, 2018: Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
- Presentation of results from ODYSSEY OUTCOMES trial - American College of Cardiology’s 67th Annual Scientific Session (ACC.18)
- ACC.18 Presentation Slides / ODYSSEY Outcomes